HIMS Form 4: Director Cosgrove awarded 3,656 RSUs vesting by mid-2026
Rhea-AI Filing Summary
Cosgrove Delos M., a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A Common Stock, with an indicated price of $0 per unit. Following the grant, the reporting person beneficially owns 3,656 shares on a direct basis.
The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, so the award is structured as a near-term retention/compensation award that will convert into ordinary shares if service conditions are met.
Positive
- 3,656 RSUs granted to a director aligns the reporting person’s interests with long-term shareholder value by tying compensation to company equity
- Near-term vesting schedule (earlier of 2026 annual meeting or June 15, 2026) supports retention through the next shareholder meeting cycle
Negative
- Potential dilution when 3,656 RSUs convert into Class A Common Stock upon vesting
- No cash consideration ($0 price) means the company will issue shares rather than receive proceeds
Insights
TL;DR: Routine director compensation via RSUs, structured for near-term vesting to retain board service.
This Form 4 reports a standard equity grant to a director: 3,656 RSUs that convert one-for-one into Class A common stock and vest at the earlier of the 2026 annual meeting or June 15, 2026, subject to continuous service. Such grants are commonly used to align director incentives with shareholders and to encourage continued board participation through the next annual meeting cycle. The direct ownership form indicates the recipient holds beneficial title to the award rather than through an indirect vehicle.
TL;DR: Small, non-cash equity issuance; immaterial to capital structure but will increase outstanding shares if settled.
The grant size (3,656 RSUs) is modest relative to typical public-company share counts and carries a stated price of $0, indicating no cash was exchanged. If and when the RSUs vest and convert to Class A shares, they will increase the count of outstanding shares by the same amount, producing a small dilution. There is no cash exercise or purchase price, and vesting is time-based through mid-2026.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 3,656 | $0.00 | -- |
Footnotes (1)
- [object Object]